Repligen Financials
RGEN Stock | USD 152.81 2.19 1.45% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 8.93 | 6.1833 |
|
|
The essential information of the day-to-day investment outlook for Repligen includes many different criteria found on its balance sheet. An individual investor should monitor Repligen's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Repligen.
Net Income |
|
Repligen | Select Account or Indicator |
Repligen Earnings Geography
Repligen Stock Summary
Repligen competes with Intuitive Surgical, ResMed, Merit Medical, ICU Medical, and Cooper Companies,. Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Repligen operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1852 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US7599161095 |
CUSIP | 759916109 |
Location | Massachusetts; U.S.A |
Business Address | Building 1, Waltham, |
Sector | Life Sciences Tools & Services |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.repligen.com |
Phone | 781 250 0111 |
Currency | USD - US Dollar |
Repligen Key Financial Ratios
Return On Equity | -0.013 | ||||
Profit Margin | (0.04) % | ||||
Operating Margin | 0.05 % | ||||
Price To Sales | 13.33 X | ||||
Revenue | 634.44 M |
Repligen Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 1.9B | 2.4B | 2.5B | 2.8B | 2.8B | 3.0B | |
Other Current Liab | 36.3M | 70.5M | 63.3M | 46.4M | 53.2M | 55.9M | |
Net Debt | (441.9M) | (237.8M) | (100.5M) | (39.5M) | (35.6M) | (37.3M) | |
Retained Earnings | 65.8M | 194.1M | 397.3M | 438.8M | 504.7M | 529.9M | |
Cash | 717.3M | 603.8M | 523.5M | 751.3M | 864.0M | 907.2M | |
Net Receivables | 71.4M | 117.4M | 116.2M | 124.2M | 142.8M | 149.9M | |
Inventory | 95.0M | 184.5M | 238.3M | 202.3M | 232.7M | 244.3M | |
Other Current Assets | 18.7M | 25.9M | 19.8M | 33.2M | 33.5M | 35.2M | |
Total Liab | 373.7M | 608.3M | 614.0M | 853.2M | (2.0B) | (1.9B) | |
Total Current Assets | 902.4M | 931.7M | 998.1M | 1.1B | 784.0M | 823.2M | |
Accounts Payable | 16.9M | 36.2M | 27.6M | 19.6M | 22.5M | 23.6M | |
Short Term Debt | 249.0M | 263.6M | 291.6M | 75.1M | 86.3M | 99.8M | |
Other Assets | 28.2M | 2.5M | 1.7M | 6.5M | 5.8M | 6.1M | |
Common Stock | 548K | 553K | 556K | 558K | 641.7K | 406.8K | |
Other Liab | 32.3M | 28.4M | 130.5M | 78.4M | 90.1M | 94.6M | |
Good Will | 618.3M | 860.4M | 855.5M | 987.1M | 1.1B | 1.2B | |
Intangible Assets | 287.1M | 337.3M | 353.7M | 400.5M | 460.6M | 483.6M | |
Net Tangible Assets | 378.8M | 623.7M | 552.4M | 701.5M | 806.7M | 847.1M | |
Capital Surpluse | 1.1B | 1.5B | 1.6B | 1.5B | 1.8B | 1.9B |
Repligen Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Interest Expense | 12.1M | 12.7M | 1.2M | 10.0M | 9.0M | 9.5M | |
Total Revenue | 366.3M | 670.5M | 801.5M | 638.8M | 634.4M | 766.2M | |
Gross Profit | 209.6M | 391.3M | 455.7M | 284.2M | 319.5M | 534.2M | |
Operating Income | 42.5M | 133.5M | 133.6M | 54.6M | (35.1M) | (36.9M) | |
Ebit | 74.6M | 173.1M | 195.9M | 56.2M | 45.0M | 47.2M | |
Ebitda | 101.6M | 211.6M | 246.9M | 124.3M | 113.3M | 119.0M | |
Cost Of Revenue | 156.6M | 279.3M | 345.8M | 354.5M | 314.9M | 232.0M | |
Income Before Tax | 59.2M | 153.5M | 219.1M | 64.1M | (27.0M) | (28.4M) | |
Net Income | 59.9M | 128.3M | 186.0M | 41.6M | (25.5M) | (26.8M) | |
Income Tax Expense | (709K) | 25.3M | 33.2M | 22.6M | 1.5M | 1.4M | |
Research Development | 20.2M | 34.3M | 43.9M | 42.7M | 43.2M | 41.0M | |
Tax Provision | (709K) | 25.3M | 33.2M | 10.1M | 11.6M | 7.4M | |
Net Interest Income | (12.1M) | (12.7M) | (3.0M) | (2.9M) | (3.3M) | (3.5M) |
Repligen Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (29.3M) | (89.8M) | (57.2M) | 41.0M | 36.9M | 38.7M | |
Change In Cash | 179.9M | (113.5M) | (80.4M) | 227.9M | (751.3M) | (713.8M) | |
Free Cash Flow | 36.3M | 47.7M | 38.7M | 74.9M | 86.2M | 90.5M | |
Depreciation | 27.1M | 38.4M | 51.0M | 68.1M | 78.3M | 82.2M | |
Other Non Cash Items | 11.2M | 20.4M | (27.0M) | (15.0M) | 3.2M | 3.3M | |
Capital Expenditures | 26.3M | 71.3M | 133.3M | 39.0M | 44.8M | 30.7M | |
Net Income | 59.9M | 128.3M | 186.0M | 41.6M | (25.5M) | (26.8M) | |
End Period Cash Flow | 717.3M | 603.8M | 523.5M | 751.3M | 864.0M | 907.2M | |
Investments | (201.4M) | (221.2M) | (100M) | (74.7M) | (67.2M) | (70.6M) | |
Change Receivables | (7.8M) | (20.9M) | (46.5M) | (3.6M) | (3.2M) | (3.4M) | |
Change To Netincome | 18.5M | 13.3M | 34.9M | 25.9M | 29.7M | 31.2M |
Repligen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Repligen's current stock value. Our valuation model uses many indicators to compare Repligen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Repligen competition to find correlations between indicators driving Repligen's intrinsic value. More Info.Repligen is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Repligen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Repligen's earnings, one of the primary drivers of an investment's value.Repligen's Earnings Breakdown by Geography
Repligen Systematic Risk
Repligen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Repligen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Repligen correlated with the market. If Beta is less than 0 Repligen generally moves in the opposite direction as compared to the market. If Repligen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Repligen is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Repligen is generally in the same direction as the market. If Beta > 1 Repligen moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Repligen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Repligen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Repligen growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Repligen March 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Repligen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Repligen. We use our internally-developed statistical techniques to arrive at the intrinsic value of Repligen based on widely used predictive technical indicators. In general, we focus on analyzing Repligen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Repligen's daily price indicators and compare them against related drivers.
Downside Deviation | 3.09 | |||
Information Ratio | 0.0523 | |||
Maximum Drawdown | 19.94 | |||
Value At Risk | (3.81) | |||
Potential Upside | 4.79 |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.83) | Earnings Share (0.47) | Revenue Per Share | Quarterly Revenue Growth 0.006 | Return On Assets |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.